Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29658344 | 1.00 | CD274 (0.66) | CD274EPHX2TSHRALDH1A1HTR1A | |
| SCHEMBL28735408 | 0.89 | MEN1 (0.60) | CD274EPHX2ALDH1A1KCNH2CYP1A2 | |
| SCHEMBL29658372 | 0.89 | MEN1 (0.63) | CD274EPHX2ALDH1A1KCNH2POLB | |
| SCHEMBL28735422 | 0.89 | MEN1 (0.63) | CD274EPHX2ALDH1A1KCNH2POLB | |
| SCHEMBL29658312 | 0.89 | MEN1 (0.60) | CD274EPHX2ALDH1A1KCNH2CYP1A2 | |
| SCHEMBL28735420 | 0.88 | MEN1 (0.62) | CD274EPHX2ALDH1A1KCNH2KDM4E | |
| SCHEMBL29658388 | 0.88 | MEN1 (0.62) | CD274EPHX2ALDH1A1KCNH2KDM4E | |
| SCHEMBL28735410 | 0.85 | MEN1 (0.49) | CD274EPHX2TSHRHTR1AKCNH2 | |
| SCHEMBL28735456 | 0.85 | MEN1 (0.49) | CD274EPHX2HTR1AKCNH2 | |
| SCHEMBL15516267 | 0.83 | EPHX2 (0.62) | CD274EPHX2TSHRALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114478366-A | Pyridone derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-9796742-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-9790209-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-2890460-B1 | KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-02-22 | — | — | EP | disclosed |
| US-20160340343-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20160340375-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| US-20150225373-A1 | KINASE INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1802586-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006044823-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | CD274 3050/4885EPHX2 778/4885TSHR 3222/4885 |
| US-20150225373-A1 | KINASE INHIBITORS | SYK, SRC, BTK | CD274 2589/4885EPHX2 1633/4885TSHR 1980/4885 |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | IRAK3, IRAK1, MAP3K1 | CD274 3050/4885EPHX2 778/4885TSHR 3222/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | CD274 4013/4885EPHX2 1269/4885TSHR 2958/4885 |
| US-20160340375-A1 | KINASE INHIBITORS | SYK, LYN, BTK | CD274 2896/4885EPHX2 1905/4885TSHR 1664/4885 |
| US-20160340343-A1 | KINASE INHIBITORS | SYK, LYN, BTK | CD274 2958/4885EPHX2 1516/4885TSHR 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.